USFDA gives nod to Zydus for Roflumilast Tablets

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

173
USFDA Approval
USFDA Approval

Last Updated on October 11, 2024 by The Health Master

Ahmedabad: Zydus Pharmaceuticals Inc. has received final approval from the USFDA to market Roflumilast Tablets in the strength of 500 mcg.

This comes along with a tentative approval for Roflumilast Tablets in the strength of 250 mcg, generic bioequivalent to Reference Listed Drug Daliresp.

Zydus being one of the first applicants for Roflumilast Tablets (500 mcg) is eligible for 180 days of shared generic drug exclusivity under section 505(j)(5)(B)(iv) of the FD&C Act.

Zydus’ Roflumilast Tablets are indicated as a treatment to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 327 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

USFDA gives nod to Lupin for Arformoterol Tartrate inhalation solution

USFDA gives nod to Granules India for generic antidepressant drug

USFDA gives tentative nod to Alembic for Fesoterodine fumarate extended-release tablets

USFDA gives nod to Granules Pharma for potassium chloride for oral solution

USFDA gives nod to Glenmark this for Blood Pressure drug

USFDA gives Orphan Drug Designation to Eplontersen

Pharmacist के बिना बिजनेस शुरू करने का मौका, 12वीं पास बेच सकेंगे Medical Devices

Imp: 15 things not to do when using a Rapid Antigen Covid Test

Licenses of two Pharma Companies suspended: NDPS Act

WHO adds this drug to Covid medicines list for severe cases

Govt issues notification on stockpiling of new drug under phase III Clinical trial

Drug alert: 27 out of 1227 samples declared as NSQ in January 2022

Gap in Price of Branded and Janaushadhi Medicine

DTAB recommendations to DCGI granting licenses under Clinical Trial

Govt issues draft notification on amendment on sale of Medical Devices

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news